clinical trial · NCT05869643
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
ST Pharm Co., Ltd.·phase2·recruiting·n = 36
HIV-1-infectionLow-dose STP0404 (Pirmitegravir)Medium-dose STP0404 (Pirmitegravir)High-dose STP0404 (Pirmitegravir)Placebo
brief summary
The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
started
May 23, 2023
primary completion
Apr 10, 2026
completion
Apr 30, 2026
last updated
Mar 11, 2026
official title
A Phase 2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Investigate the Antiviral Effect, Safety, Tolerability, and Pharmacokinetics of STP0404 in Adults With HIV-1 Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol